Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Briacell Therapeutics Corp
T.BCT
Alternate Symbol(s):
BCTX
|
BCTXW
Healthcare
Biotechnology
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted...
immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:BCT)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Next
(17)
•••
drongodragon
X
View Profile
View Bullboard History
Comment by
drongodragon
on Nov 21, 2024 4:40pm
RE:RE:price pivot is around $1,20
Don't know who the clown is but I am watching with today's move.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Nov 21, 2024 7:50am
New Press Release - BriaCell Announces First Patient Dosed with Bria-OTS(TM) in Metastatic Breast Cancer Study
Phase 1/2 dose escalation study to evaluate BriaCell’s personalized next generation immunotherapy treatment in metastatic breast cancerBria-OTS™ to be studied as monotherapy and in combination with BeiGene’s anti-PD-1 antibodyPHILADELPHIA and VANCOUVER, British Columbia, Nov. 21, 2024 (GLOBE...
read article.
•••
Jonathon Brown
X
View Profile
View Bullboard History
Post by
Jonathon Brown
on Nov 21, 2024 6:55am
Buzz on the Bullboards: Bombardier, world woes, a smart fridge, and top shelf weed
A highlight of the week was Bombardier (TSX:BBD), which reported impressive growth in its Q3 2024 results.
read article.
(20)
•••
wallpaper2
X
View Profile
View Bullboard History
Comment by
wallpaper2
on Nov 17, 2024 4:40am
RE:price pivot is around $1,20
A mive to 1.60. Watch and learn wtf. Who is this cliwn?
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Nov 08, 2024 7:51am
New Press Release - BriaCell Showcases Robust Anti-Cancer Activity of Personalized Off-the-Shelf Immunotherapy Pipeline at the 2024 SITC Conference
BriaCell’s clinical candidates for next generation breast cancer (Bria-BRES+™) and prostate cancer (Bria-PROS+™) generate robust anti-cancer activity in preclinical modelsNovel therapy activates both innate and adaptive immune systemsProof of concept Phase 1/2 Study of Bria-BRES™ in metastatic...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Nov 04, 2024 7:51am
New Press Release - BriaCell Overall Survival Data Selected for Spotlight Poster at 2024 San Antonio Breast Cancer Symposium®, December 10 - 13
Five BriaCell poster presentations to highlight updated survival and key biomarker data from Phase 2 trial of Bria-IMT™ plus immune check point inhibitor in metastatic breast cancerPresentations include planned Phase 3 study design expanding use of Bria-IMT™ + CPI to any cancer patient with...
read article.
(250)
•••
loopsbutterfly
X
View Profile
View Bullboard History
Comment by
loopsbutterfly
on Oct 30, 2024 1:24pm
RE:price pivot is around $1,20
I have been wrong...at least in the short term last trade $1,08
(250)
•••
loopsbutterfly
X
View Profile
View Bullboard History
Post by
loopsbutterfly
on Oct 28, 2024 1:00pm
price pivot is around $1,20
a move to $1,60 is very likely...stay tune just watch and learn gracias grinnnnn....
(250)
•••
loopsbutterfly
X
View Profile
View Bullboard History
Comment by
loopsbutterfly
on Oct 22, 2024 10:55am
RE:Mid 2025 means late 2025..early 2026
I bought back some shares lately....it is way too low. At some point a major can jump into the bankwagon for a take over... a good gambling at this level !!!
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Oct 22, 2024 7:50am
New Press Release - BriaCell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival Data
55% of BriaCell patients1 remained alive one year since enrollment in BriaCell’s Phase 2 study, markedly exceeding the survival rate of current standard of care for similar patientsMultiple outperforming patients with overall survival of over 2 yearsSurvival benefit observed even in heavily pre...
read article.
(20)
•••
wallpaper2
X
View Profile
View Bullboard History
Post by
wallpaper2
on Oct 16, 2024 2:56pm
Mid 2025 means late 2025..early 2026
Hope to have enrollment next summer?? 6 months to complete and analyze takes us to late 2025-2026 at the earliest.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Oct 15, 2024 7:50am
New Press Release - BriaCell Provides Phase 3 Clinical Engagement Update in Metastatic Breast Cancer Pivotal Study
35 sites active and enrolling in pivotal Phase 3 study of Bria-IMT™ combination with immune check point inhibitor in metastatic breast cancer (MBC)Primary endpoint is overall survival (OS) with Bria-IMT™ regimen plus Check Point Inhibitor (CPI) vs treatment of physician’s choiceInterim data...
read article.
(250)
•••
loopsbutterfly
X
View Profile
View Bullboard History
Comment by
loopsbutterfly
on Oct 02, 2024 8:50pm
RE:RE:Going back up to $8?
a nice swing trade today...out at $1,37 near the close gracias grinnnnn..
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Oct 02, 2024 4:05pm
New Press Release - BriaCell Therapeutics Announces Closing of $5 Million Offering
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 02, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the...
read article.
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Comment by
Iseneschal
on Oct 02, 2024 3:37pm
RE:Going back up to $8?
How did QNTM work out for u?
(250)
•••
loopsbutterfly
X
View Profile
View Bullboard History
Comment by
loopsbutterfly
on Oct 02, 2024 2:48pm
RE:Going back up to $8?
I do agree and that's why I bought back on the cheap lately some as low as $0.66 per share gracias grinnnnn...
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >